QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods
  • Alhossain A. Khalafallah
    Launceston General Hospital, Tasmania, Australia | alhossain@yahoo.com
  • Kristina McDonnell
    Launceston General Hospital, Tasmania, Australia
  • Hizb U. Dawar
    Launceston General Hospital, Tasmania, Australia
  • Iain Robertson
    School of Human Life Sciences, Tasmania, Australia, Australia
  • David Woods
    Launceston General Hospital, Tasmania, Australia

Abstract

Few studies exist that consider health-related quality of life (HR-QOL) in patients with multiple myeloma (MM) undergoing tandem autologous stem cell transplantation (TASCT).

Eighteen patients with advanced MM who underwent dose-modified TASCT were enrolled in this study between March 2006 and March 2008. Patients <60 year old (10) received conditioning with melphalan 140 mg/m2 and patients who were ≥60 years (8) received 100 mg/m2. The median age was 57.5 years (range 35-69). We conducted the European Organization of Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire via interviews at presentation, after each ASCT and thereafter every 3 months for 24 months. Mean global health measure improved from 3.44 before transplant to 4.50 (1=very poor, 7=excellent) at the second and subsequent follow-up visits (P<0.001) and the mean global quality of life score improved from 3.61 to 4.71 (P<0.001). Pain symptom was reduced (P=0.001), and physical functioning improved (P<0.001) throughout the period of post-transplant follow-up.

Our study showed that dose-reduced TASCT is well tolerated with low toxicity albeit the transient reduction in QOL during both transplants. Post-transplant follow-up showed significant improvement in overall HR-QOL that reflects positively in the overall disease-outcome.    The EORTC-QLQ-C30 is a practical tool in measuring QOL in myeloma patients.

Keywords

Tandem autologous stem cell transplantation, dose-reduced, multiple myeloma, health-related quality of life, EORTC QLQ-C30.

Full Text:

PDF
HTML
Submitted: 2014-06-12 16:03:59
Published: 2011-11-28 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
365

Views:
PDF
82
HTML
1099

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185